Loading...

Arie Belldegrun

Title(s)Professor-in-Residence, Urology
SchoolMedicine
Address924 Westwood Boulevard 1000
Los Angeles CA 90024
Phone61434
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Chemoprevention of Superficial Bladder Cancer
    NIH/NCI U01CA096116Aug 7, 2002 - Mar 31, 2007
    Role: Principal Investigator
    TUMOR SPECIFIC TIL FROM RENAL CANCER
    NIH/NCI R29CA052499Aug 15, 1990 - Jul 31, 1995
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. A Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9 (DC-AdGMCAIX) in Patients With Metastatic Renal Cell Carcinoma. J Immunother. 2020 Nov/Dec; 43(9):273-282. Faiena I, Comin-Anduix B, Berent-Maoz B, Bot A, Zomorodian N, Sachdeva A, Said J, Cheung-Lau G, Pang J, Macabali M, Chodon T, Wang X, Cabrera P, Kaplan-Lefko P, Chamie K, Belldegrun AS, Pantuck AJ, Drakaki A. PMID: 32925563.
      View in: PubMed   Mentions: 1     Fields:    
    2. Evaluation of the prognostic role of co-morbidities on disease outcome in renal cell carcinoma patients. World J Urol. 2020 Jun; 38(6):1525-1533. Heide J, Ribback S, Klatte T, Shariat S, Burchardt M, Dombrowski F, Belldegrun AS, Drakaki A, Pantuck AJ, Kroeger N. PMID: 31520111.
      View in: PubMed   Mentions: 1     Fields:    
    3. Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinoma. Cancer Immunol Immunother. 2019 May; 68(5):743-751. Faiena I, Astrow SH, Elashoff DA, Jain R, Bot A, Chamie K, Belldegrun AS, Pantuck AJ, Drakaki A. PMID: 30790015.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    4. Utility of multiphasic multidetector computed tomography in discriminating between clear cell renal cell carcinomas with high and low carbonic anhydrase-IX expression. Abdom Radiol (NY). 2018 10; 43(10):2734-2742. Young JR, Coy H, Kim HJ, Douek M, Sisk A, Belldegrun A, Pantuck AJ, Raman SS. PMID: 29520426.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Receptor activator of NF-κB (RANK)-mediated induction of metastatic spread and association with poor prognosis in renal cell carcinoma. Urol Oncol. 2018 11; 36(11):502.e15-502.e24. Steven A, Leisz S, Fussek S, Nowroozizadeh B, Huang J, Branstetter D, Dougall WC, Burchardt M, Belldegrun AS, Seliger B, Pantuck A, Kroeger N. PMID: 30170981.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    6. Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma. Urol Oncol. 2018 02; 36(2):78.e21-78.e28. Lenis AT, Salmasi AH, Donin NM, Faiena I, Johnson DC, Drakaki A, Gollapudi K, Blumberg J, Belldegrun AS, Pantuck AJ, Chamie K. PMID: 29128421.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    7. Overall survival in patients with metastatic renal cell carcinoma and clinical N1 disease undergoing cytoreductive nephrectomy and lymph node dissection. Urol Oncol. 2018 02; 36(2):79.e19-79.e26. Faiena I, Salmasi A, Lenis AT, Donin NM, Johnson DC, Bachour K, Drakaki A, Belldegrun AS, Pantuck AJ, Chamie K. PMID: 29103965.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    8. Role of surgical approach on lymph node dissection yield and survival in patients with upper tract urothelial carcinoma. Urol Oncol. 2018 01; 36(1):9.e1-9.e9. Lenis AT, Donin NM, Faiena I, Salmasi A, Johnson DC, Drakaki A, Gollapudi K, Blumberg J, Belldegrun A, Pantuck A, Chamie K. PMID: 29066013.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    9. Recognizing the Continuous Nature of Expression Heterogeneity and Clinical Outcomes in Clear Cell Renal Cell Carcinoma. Sci Rep. 2017 08 04; 7(1):7342. Wei X, Choudhury Y, Lim WK, Anema J, Kahnoski RJ, Lane B, Ludlow J, Takahashi M, Kanayama HO, Belldegrun A, Kim HL, Rogers C, Nicol D, Teh BT, Tan MH. PMID: 28779136.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    10. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial. JAMA Oncol. 2017 Jul 01; 3(7):913-920. Chamie K, Donin NM, Klöpfer P, Bevan P, Fall B, Wilhelm O, Störkel S, Said J, Gambla M, Hawkins RE, Jankilevich G, Kapoor A, Kopyltsov E, Staehler M, Taari K, Wainstein AJA, Pantuck AJ, Belldegrun AS. PMID: 27787547.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    11. Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials. J Urol. 2018 01; 199(1):43-52. Lenis AT, Donin NM, Johnson DC, Faiena I, Salmasi A, Drakaki A, Belldegrun A, Pantuck A, Chamie K. PMID: 28479237.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    12. Serial retrograde instillations of sustained release formulation of mitomycin C to the upper urinary tract of the Yorkshire swine using a thermosensitive polymer: Safety and feasibility. Urol Oncol. 2017 05; 35(5):272-278. Donin NM, Strauss-Ayali D, Agmon-Gerstein Y, Malchi N, Lenis AT, Holden S, Pantuck AJ, Belldegrun AS, Chamie K. PMID: 28065395.
      View in: PubMed   Mentions: 3     Fields:    Translation:Animals
    13. A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer. Urol Oncol. 2017 02; 35(2):39.e1-39.e7. Donin NM, Chamie K, Lenis AT, Pantuck AJ, Reddy M, Kivlin D, Holldack J, Pozzi R, Hakim G, Karsh LI, Lamm DL, Belkoff LH, Belldegrun AS, Holden S, Shore N. PMID: 28341495.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    14. Sustained-release Formulation of Mitomycin C to the Upper Urinary Tract Using a Thermosensitive Polymer: A Preclinical Study. Urology. 2017 Jan; 99:270-277. Donin NM, Duarte S, Lenis AT, Caliliw R, Torres C, Smithson A, Strauss-Ayali D, Agmon-Gerstein Y, Malchi N, Said J, Raman SS, Holden S, Pantuck A, Belldegrun AS, Chamie K. PMID: 27720772.
      View in: PubMed   Mentions: 5     Fields:    Translation:Animals
    15. Immunotherapy for the Treatment of Urothelial Carcinoma. J Urol. 2017 01; 197(1):14-22. Donin NM, Lenis AT, Holden S, Drakaki A, Pantuck A, Belldegrun A, Chamie K. PMID: 27460757.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    16. Body Mass Index and Survival in a Prospective Randomized Trial of Localized High-Risk Renal Cell Carcinoma. Cancer Epidemiol Biomarkers Prev. 2016 09; 25(9):1326-32. Donin NM, Pantuck A, Klöpfer P, Bevan P, Fall B, Said J, Belldegrun AS, Chamie K. PMID: 27418270.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    17. Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Proc Natl Acad Sci U S A. 2016 Feb 23; 113(8):2170-5. Bi M, Zhao S, Said JW, Merino MJ, Adeniran AJ, Xie Z, Nawaf CB, Choi J, Belldegrun AS, Pantuck AJ, Kluger HM, Bilgüvar K, Lifton RP, Shuch B. PMID: 26864202.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    18. Words of wisdom. Re: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. Eur Urol. 2015 Apr; 67(4):816-7. Daskivich TJ, Belldegrun A. PMID: 25765212.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    19. Carbonic anhydrase-IX score is a novel biomarker that predicts recurrence and survival for high-risk, nonmetastatic renal cell carcinoma: Data from the phase III ARISER clinical trial. Urol Oncol. 2015 May; 33(5):204.e25-33. Chamie K, Klöpfer P, Bevan P, Störkel S, Said J, Fall B, Belldegrun AS, Pantuck AJ. PMID: 25823535.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    20. The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015 Feb 01; 21(3):561-8. McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin RA, Pantuck AJ, Regan MM, Atkins MB. PMID: 25424850.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCTClinical Trials
    21. The preoperative prognostic nutritional index is an independent predictor of survival in patients with renal cell carcinoma. Urol Oncol. 2015 Feb; 33(2):68.e1-7. Hofbauer SL, Pantuck AJ, de Martino M, Lucca I, Haitel A, Shariat SF, Belldegrun AS, Klatte T. PMID: 25240758.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    22. Nephron-sparing surgery is superior to radical nephrectomy in preserving renal function benefit even when expanding indications beyond the traditional 4-cm cutoff. Urol Oncol. 2014 Oct; 32(7):1024-30. Pignot G, Bigot P, Bernhard JC, Bouliere F, Bessede T, Bensalah K, Salomon L, Mottet N, Bellec L, Soulié M, Ferrière JM, Pfister C, Drai J, Colombel M, Villers A, Rigaud J, Bouchot O, Montorsi F, Bertini R, Belldegrun AS, Pantuck AJ, Patard JJ. PMID: 24996775.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    23. The contemporary role on surgery in the management of renal masses. World J Urol. 2014 Jun; 32(3):571-2. Kroeger N, Belldegrun AS, Pantuck AJ. PMID: 24718636.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    24. The contemporary role of ablative treatment approaches in the management of renal cell carcinoma (RCC): focus on radiofrequency ablation (RFA), high-intensity focused ultrasound (HIFU), and cryoablation. World J Urol. 2014 Jun; 32(3):597-605. Klatte T, Kroeger N, Zimmermann U, Burchardt M, Belldegrun AS, Pantuck AJ. PMID: 24700308.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    25. Poor prognosis and advanced clinicopathological features of clear cell renal cell carcinoma (ccRCC) are associated with cytoplasmic subcellular localisation of Hypoxia inducible factor-2a. Eur J Cancer. 2014 May; 50(8):1531-40. Kroeger N, Seligson DB, Signoretti S, Yu H, Magyar CE, Huang J, Belldegrun AS, Pantuck AJ. PMID: 24565854.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    26. PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity. Anticancer Res. 2013 Aug; 33(8):2997-3004. Logan JE, Mostofizadeh N, Desai AJ, VON Euw E, Conklin D, Konkankit V, Hamidi H, Eckardt M, Anderson L, Chen HW, Ginther C, Taschereau E, Bui PH, Christensen JG, Belldegrun AS, Slamon DJ, Kabbinavar FF. PMID: 23898052.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    27. Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma. J Urol. 2013 Dec; 190(6):1999-2004. de Martino M, Pantuck AJ, Hofbauer S, Waldert M, Shariat SF, Belldegrun AS, Klatte T. PMID: 23831313.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    28. Salvage-targeted kidney cancer therapy in patients progressing on high-dose interleukin-2 immunotherapy: the UCLA experience. Cancer J. 2013 May-Jun; 19(3):189-96. Birkhäuser FD, Pantuck AJ, Rampersaud EN, Wang X, Kroeger N, Pouliot F, Zomorodian N, Riss J, Li G, Kabbinavar FF, Belldegrun AS. PMID: 23708063.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    29. The effect of gender and age on kidney cancer survival: younger age is an independent prognostic factor in women with renal cell carcinoma. Urol Oncol. 2014 Jan; 32(1):30.e9-13. Rampersaud EN, Klatte T, Bass G, Patard JJ, Bensaleh K, Böhm M, Allhoff EP, Cindolo L, De La Taille A, Mejean A, Soulie M, Bellec L, Christophe Bernhard J, Pfister C, Colombel M, Belldegrun AS, Pantuck AJ, George D. PMID: 23422777.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    30. Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models. J Immunother. 2013 Feb; 36(2):102-11. Birkhäuser FD, Koya RC, Neufeld C, Rampersaud EN, Lu X, Micewicz ED, Chodon T, Atefi M, Kroeger N, Chandramouli GV, Li G, Said JW, McBride WH, Kabbinavar FF, Ribas A, Pantuck AJ, Belldegrun AS, Riss J. PMID: 23377663.
      View in: PubMed   Mentions: 11     Fields:    Translation:AnimalsCells
    31. Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma. Cancer. 2013 Apr 15; 119(8):1547-54. Kroeger N, Klatte T, Chamie K, Rao PN, Birkhäuser FD, Sonn GA, Riss J, Kabbinavar FF, Belldegrun AS, Pantuck AJ. PMID: 23335244.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    32. Gain of chromosome 8q is associated with metastases and poor survival of patients with clear cell renal cell carcinoma. Cancer. 2012 Dec 01; 118(23):5777-82. Klatte T, Kroeger N, Rampersaud EN, Birkhäuser FD, Logan JE, Sonn G, Riss J, Rao PN, Kabbinavar FF, Belldegrun AS, Pantuck AJ. PMID: 22605478.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    33. Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinoma. Eur Urol. 2012 May; 61(5):888-95. Kroeger N, Seligson DB, Klatte T, Rampersaud EN, Birkhäuser FD, Rao PN, Leppert JT, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ. PMID: 22269604.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    34. Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma. BJU Int. 2012 Jun; 109(11):1600-6. Shuch B, Bratslavsky G, Shih J, Vourganti S, Finley D, Castor B, Treat E, Linehan WM, Pantuck AJ, Said JW, Belldegrun AS. PMID: 22221668.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    35. Systemic therapy for metastatic renal cell carcinoma: a review and update. Rev Urol. 2012; 14(3-4):65-78. Logan JE, Rampersaud EN, Sonn GA, Chamie K, Belldegrun AS, Pantuck AJ, Slamon DJ, Kabbinavar FF. PMID: 23526579.
      View in: PubMed   Mentions:
    36. Prognostic value of microvascular invasion in predicting the cancer specific survival and risk of metastatic disease in renal cell carcinoma: a multicenter investigation. J Urol. 2012 Feb; 187(2):418-23. Kroeger N, Rampersaud EN, Patard JJ, Klatte T, Birkhäuser FD, Shariat SF, Lang H, Rioux-Leclerq N, Remzi M, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ. PMID: 22177164.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    37. Clear cell renal cell carcinoma: multiphasic multidetector CT imaging features help predict genetic karyotypes. Radiology. 2011 Dec; 261(3):854-62. Sauk SC, Hsu MS, Margolis DJ, Lu DS, Rao NP, Belldegrun AS, Pantuck AJ, Raman SS. PMID: 22025734.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    38. The chromophobe tumor grading system is the preferred grading scheme for chromophobe renal cell carcinoma. J Urol. 2011 Dec; 186(6):2168-74. Finley DS, Shuch B, Said JW, Galliano G, Jeffries RA, Afifi AA, Castor B, Magyar C, Sadaat A, Kabbinavar FF, Belldegrun AS, Pantuck AJ. PMID: 22014797.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    39. Smoking negatively impacts renal cell carcinoma overall and cancer-specific survival. Cancer. 2012 Apr 01; 118(7):1795-802. Kroeger N, Klatte T, Birkhäuser FD, Rampersaud EN, Seligson DB, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ. PMID: 21997347.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    40. Basic research in kidney cancer. Eur Urol. 2011 Oct; 60(4):622-33. Oosterwijk E, Rathmell WK, Junker K, Brannon AR, Pouliot F, Finley DS, Mulders PF, Kirkali Z, Uemura H, Belldegrun A. PMID: 21741760.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    41. Salvage cryotherapy for radiation-recurrent prostate cancer: outcomes and complications. Curr Urol Rep. 2011 Jun; 12(3):209-15. Finley DS, Belldegrun AS. PMID: 21394596.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    42. Cardiopulmonary bypass and renal cell carcinoma with level IV tumour thrombus: can deep hypothermic circulatory arrest limit perioperative mortality? BJU Int. 2011 Mar; 107(5):724-728. Shuch B, Crispen PL, Leibovich BC, LaRochelle JC, Pouliot F, Pantuck AJ, Liu W, Crepel M, Schuckman A, Rigaud J, Bouchot O, Patard JJ, Skinner D, Belldegrun AS, Blute ML. PMID: 20626391.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    43. Words of Wisdom. Re: randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. Eur Urol. 2011 Feb; 59(2):301-2. Rampersaud EN, Belldegrun AS. PMID: 21414876.
      View in: PubMed   Mentions:    Fields:    
    44. Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling. J Urol. 2011 Mar; 185(3):787-94. Molina A, Belldegrun A. PMID: 21239012.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    45. Tumor biology and prognostic factors in renal cell carcinoma. Oncologist. 2011; 16 Suppl 2:4-13. Finley DS, Pantuck AJ, Belldegrun AS. PMID: 21346035.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCells
    46. Ultrasound-based combination therapy: potential in urologic cancer. Expert Rev Anticancer Ther. 2011 Jan; 11(1):107-13. Finley DS, Pouliot F, Shuch B, Chin A, Pantuck A, Dekernion JB, Belldegrun AS. PMID: 21166515.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    47. Quality of pathological reporting for renal cell cancer: implications for systemic therapy, prognostication and surveillance. BJU Int. 2011 Aug; 108(3):343-8. Shuch B, Pantuck AJ, Pouliot F, Finley DS, Said JW, Belldegrun AS, Saigal C. PMID: 21087450.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    48. Immunological therapy in urological malignancy: novel combination strategies. Int J Urol. 2011 Feb; 18(2):94-101. Finley DS, Pouliot F, Chin AI, Shuch B, Pantuck AJ, Belldegrun AS, Dekernion JB. PMID: 21073543.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    49. Pathological, immunohistochemical and cytogenetic features of papillary renal cell carcinoma with clear cell features. J Urol. 2011 Jan; 185(1):30-5. Klatte T, Said JW, Seligson DB, Rao PN, de Martino M, Shuch B, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ. PMID: 21074210.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    50. Single nucleotide polymorphisms of 8 inflammation-related genes and their associations with smoking-related cancers. Int J Cancer. 2010 Nov 01; 127(9):2169-82. Oh SS, Chang SC, Cai L, Cordon-Cardo C, Ding BG, Greenland S, He N, Jiang Q, Kheifets L, Le A, Lee YC, Liu S, Lu ML, Mao JT, Morgenstern H, Mu LN, Pantuck A, Papp JC, Park SL, Rao JY, Reuter VE, Tashkin DP, Wang H, You NC, Yu SZ, Zhao JK, Belldegrun A, Zhang ZF. PMID: 20112337.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    51. Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma. Cancer. 2010 Oct 15; 116(20):4696-702. La Rochelle J, Klatte T, Dastane A, Rao N, Seligson D, Said J, Shuch B, Zomorodian N, Kabbinavar F, Belldegrun A, Pantuck AJ. PMID: 20629029.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    52. Contemporary management of renal tumors with venous tumor thrombus. J Urol. 2010 Sep; 184(3):833-41; quiz 1235. Pouliot F, Shuch B, Larochelle JC, Pantuck A, Belldegrun AS. PMID: 20643450.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    53. Fuhrman grade provides higher prognostic accuracy than nucleolar grade for papillary renal cell carcinoma. J Urol. 2010 Jun; 183(6):2143-7. Klatte T, Anterasian C, Said JW, de Martino M, Kabbinavar FF, Belldegrun AS, Pantuck AJ. PMID: 20399450.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    54. Sex, age, and surgeon decision on nephron-sparing surgery are independent predictors of renal masses with benign histologic findings--a multicenter survey. Urology. 2010 Sep; 76(3):541-6. Zisman A, Patard JJ, Raz O, Klatte T, Haifler M, Mendlovic S, Sandbank J, Belldegrun AS, Lindner A, Leibovici D, Pantuck AJ. PMID: 20494411.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    55. Development and external validation of a nomogram predicting disease specific survival after nephrectomy for papillary renal cell carcinoma. J Urol. 2010 Jul; 184(1):53-8. Klatte T, Remzi M, Zigeuner RE, Mannweiler S, Said JW, Kabbinavar FF, Haitel A, Waldert M, de Martino M, Marberger M, Belldegrun AS, Pantuck AJ. PMID: 20478577.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    56. Management and outcomes of tumor recurrence after focal ablation renal therapy. J Endourol. 2010 May; 24(5):749-52. Breda A, Anterasian C, Belldegrun A. PMID: 20443716.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    57. Absent CD44v6 expression is an independent predictor of poor urothelial bladder cancer outcome. J Urol. 2010 Jun; 183(6):2403-8. Klatte T, Seligson DB, Rao JY, Yu H, de Martino M, Garraway I, Wong SG, Belldegrun AS, Pantuck AJ. PMID: 20403620.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    58. Predictive factors for ipsilateral recurrence after nephron-sparing surgery in renal cell carcinoma. Eur Urol. 2010 Jun; 57(6):1080-6. Bernhard JC, Pantuck AJ, Wallerand H, Crepel M, Ferrière JM, Bellec L, Maurice-Tison S, Robert G, Albouy B, Pasticier G, Soulie M, Lopes D, Lacroix B, Bensalah K, Pfister C, Thuret R, Tostain J, De La Taille A, Salomon L, Abbou C, Colombel M, Belldegrun AS, Patard JJ. PMID: 20188458.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    59. Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy. Cancer. 2010 Feb 01; 116(3):616-24. Shuch B, Said J, LaRochelle JC, Zhou Y, Li G, Klatte T, Pouliot F, Kabbinavar FF, Belldegrun AS, Pantuck AJ. PMID: 19998348.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    60. Primary and salvage cryotherapy for prostate cancer. Urol Clin North Am. 2010 Feb; 37(1):67-82, Table of Contents. Finley DS, Pouliot F, Miller DC, Belldegrun AS. PMID: 20152521.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    61. Comparison of accuracy of 14-, 18- and 20-G needles in ex-vivo renal mass biopsy: a prospective, blinded study. BJU Int. 2010 Apr; 105(7):940-5. Breda A, Treat EG, Haft-Candell L, Leppert JT, Harper JD, Said J, Raman S, Smith RB, Belldegrun AS, Schulam PG. PMID: 19888984.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    62. Conditional survival predictions after nephrectomy for renal cell carcinoma. J Urol. 2009 Dec; 182(6):2607-12. Karakiewicz PI, Suardi N, Capitanio U, Isbarn H, Jeldres C, Perrotte P, Sun M, Ficarra V, Zigeuner R, Tostain J, Mejean A, Cindolo L, Pantuck AJ, Belldegrun AS, Zini L, de la Taille A, Chautard D, Descotes JL, Shariat SF, Valeri A, Mulders PF, Lang H, Lechevallier E, Patard JJ. PMID: 19836798.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    63. Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology--is up-front resection indicated and, if not, is it avoidable? J Urol. 2009 Nov; 182(5):2164-71. Shuch B, Said J, La Rochelle JC, Zhou Y, Li G, Klatte T, Kabbinaavar FF, Pantuck AJ, Belldegrun AS. PMID: 19758641.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    64. Editorial comment. Urology. 2009 Sep; 74(3):641-2; author reply 642. Pouliot F, Belldegrun A. PMID: 19716921.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    65. CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis. J Urol. 2009 Aug; 182(2):728-34. de Martino M, Klatte T, Seligson DB, LaRochelle J, Shuch B, Caliliw R, Li Z, Kabbinavar FF, Pantuck AJ, Belldegrun AS. PMID: 19539328.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    66. Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker. Cancer. 2009 Apr 01; 115(7):1448-58. Klatte T, Seligson DB, Rao JY, Yu H, de Martino M, Kawaoka K, Wong SG, Belldegrun AS, Pantuck AJ. PMID: 19195047.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    67. Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol. 2010 Mar; 57(3):466-71. Bensalah K, Pantuck AJ, Rioux-Leclercq N, Thuret R, Montorsi F, Karakiewicz PI, Mottet N, Zini L, Bertini R, Salomon L, Villers A, Soulie M, Bellec L, Rischmann P, De la Taille A, Avakian R, Crepel M, Ferriere JM, Bernhard JC, Dujardin T, Pouliot F, Rigaud J, Pfister C, Albouy B, Guy L, Joniau S, van Poppel H, Lebret T, Culty T, Saint F, Zisman A, Raz O, Lang H, Spie R, Wille A, Roigas J, Aguilera A, Rambeaud B, Martinez Piñeiro L, Nativ O, Farfara R, Richard F, Roupret M, Doehn C, Bastian PJ, Muller SC, Tostain J, Belldegrun AS, Patard JJ. PMID: 19359089.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    68. Functional and oncological outcomes of partial nephrectomy of solitary kidneys. J Urol. 2009 May; 181(5):2037-42; discussion 2043. La Rochelle J, Shuch B, Riggs S, Liang LJ, Saadat A, Kabbinavar F, Pantuck A, Belldegrun A. PMID: 19298974.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    69. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol Biomarkers Prev. 2009 Mar; 18(3):894-900. Klatte T, Seligson DB, LaRochelle J, Shuch B, Said JW, Riggs SB, Zomorodian N, Kabbinavar FF, Pantuck AJ, Belldegrun AS. PMID: 19240241.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    70. Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classification. J Urol. 2009 Apr; 181(4):1558-64; discussion 1563-4. Klatte T, Said JW, de Martino M, Larochelle J, Shuch B, Rao JY, Thomas GV, Kabbinavar FF, Belldegrun AS, Pantuck AJ. PMID: 19230920.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    71. Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin Cancer Res. 2009 Feb 15; 15(4):1162-9. Klatte T, Pantuck AJ, Said JW, Seligson DB, Rao NP, LaRochelle JC, Shuch B, Zisman A, Kabbinavar FF, Belldegrun AS. PMID: 19228721.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    72. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol. 2009 Feb 10; 27(5):746-53. Klatte T, Rao PN, de Martino M, LaRochelle J, Shuch B, Zomorodian N, Said J, Kabbinavar FF, Belldegrun AS, Pantuck AJ. PMID: 19124809.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansCells
    73. Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL. Rev Urol. 2009; 11(2):82-107. Brawer MK, Loeb S, Partin AW, Yoshimura N, Chancellor MB, Roehrborn CG, Assimos DG, Nickel JC, Shuch B, Pouliot F, Belldegrun AS, Shapiro E. PMID: 19680529.
      View in: PubMed   Mentions:
    74. Intraoperative thrombus embolization during nephrectomy and tumor thrombectomy: critical analysis of the University of California-Los Angeles experience. J Urol. 2009 Feb; 181(2):492-8; discussion 498-9. Shuch B, Larochelle JC, Onyia T, Vallera C, Margulis D, Pantuck AJ, Smith RB, Belldegrun AS. PMID: 19110280.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    75. Associations between variants of the 8q24 chromosome and nine smoking-related cancer sites. Cancer Epidemiol Biomarkers Prev. 2008 Nov; 17(11):3193-202. Park SL, Chang SC, Cai L, Cordon-Cardo C, Ding BG, Greenland S, Hussain SK, Jiang Q, Liu S, Lu ML, Mao JT, Morgenstern H, Mu LN, Ng LJ, Pantuck A, Rao J, Reuter VE, Tashkin DP, You NC, Yu CQ, Yu SZ, Zhao JK, Belldegrun A, Zhang ZF. PMID: 18990762.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    76. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies. Cancer. 2008 Nov 01; 113(9):2457-63. Belldegrun AS, Klatte T, Shuch B, LaRochelle JC, Miller DC, Said JW, Riggs SB, Zomorodian N, Kabbinavar FF, Dekernion JB, Pantuck AJ. PMID: 18823034.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    77. Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer. 2008 Oct 01; 113(7):1641-8. Shuch B, La Rochelle JC, Klatte T, Riggs SB, Liu W, Kabbinavar FF, Pantuck AJ, Belldegrun AS. PMID: 18671240.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    78. Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance. Cancer. 2008 Sep 15; 113(6):1324-31. Shuch B, La Rochelle JC, Wu J, Klatte T, Riggs SB, Kabbinavar F, Belldegrun AS, Pantuck AJ. PMID: 18661529.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    79. Partial nephrectomy: a contemporary review regarding outcomes and different techniques. Cancer J. 2008 Sep-Oct; 14(5):302-7. Riggs SB, Larochelle JC, Belldegrun AS. PMID: 18836334.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    80. The staging of renal cell carcinoma. Curr Opin Urol. 2008 Sep; 18(5):455-61. Shuch B, La Rochelle JC, Pantuck AJ, Belldegrun AS. PMID: 18670267.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    81. Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-kappaB-dependent mechanism. . 2008 Sep; 7(9):2662-71. Rettig MB, Heber D, An J, Seeram NP, Rao JY, Liu H, Klatte T, Belldegrun A, Moro A, Henning SM, Mo D, Aronson WJ, Pantuck A. PMID: 18790748.
      View in: PubMed   Mentions:
    82. Prognostic variables to predict cancer-related death in incidental renal tumours. BJU Int. 2008 Nov; 102(10):1376-80. Bensalah K, Pantuck AJ, Crepel M, Verhoest G, Méjean A, Valéri A, Ficarra V, Pfister C, Ferrière JM, Soulié M, Cindolo L, De La Taille A, Tostain J, Chautard D, Schips L, Zigeuner R, Abbou CC, Lobel B, Salomon L, Lechevallier E, Descotes JL, Guillé F, Colombel M, Belldegrun AS, Patard JJ. PMID: 18727618.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    83. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer. 2008 Jul 15; 123(2):395-400. Patard JJ, Fergelot P, Karakiewicz PI, Klatte T, Trinh QD, Rioux-Leclercq N, Said JW, Belldegrun AS, Pantuck AJ. PMID: 18464292.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCells
    84. Carbonic anhydrase IX as a predictive biomarker for clear cell renal cell carcinoma. J Clin Oncol. 2008 Jun 20; 26(18):3105-7; author reply 3107-9. Pantuck AJ, Klatte T, Seligson D, Atkins M, Belldegrun A. PMID: 18565906.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    85. The role of carbonic anhydrase IX as a molecular marker for transitional cell carcinoma of the bladder. BJU Int. 2008 Jun; 101 Suppl 4:45-8. Klatte T, Belldegrun AS, Pantuck AJ. PMID: 18430124.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    86. Carbonic anhydrase IX and renal cell carcinoma: prognosis, response to systemic therapy, and future vaccine strategies. BJU Int. 2008 Jun; 101 Suppl 4:25-30. Shuch B, Li Z, Belldegrun AS. PMID: 18430119.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    87. Re: efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. Eur Urol. 2008 May; 53(5):1085-6. Shuch B, Belldegrun A. PMID: 18485320.
      View in: PubMed   Mentions: 2     Fields:    
    88. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int. 2008 Sep; 102(6):692-6. Shuch B, Riggs SB, LaRochelle JC, Kabbinavar FF, Avakian R, Pantuck AJ, Patard JJ, Belldegrun AS. PMID: 18410444.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    89. Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. J Urol. 2008 May; 179(5):1719-26. Klatte T, Patard JJ, de Martino M, Bensalah K, Verhoest G, de la Taille A, Abbou CC, Allhoff EP, Carrieri G, Riggs SB, Kabbinavar FF, Belldegrun AS, Pantuck AJ. PMID: 18343437.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    90. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res. 2008 Jan 15; 14(2):502-8. Weiner LM, Belldegrun AS, Crawford J, Tolcher AW, Lockbaum P, Arends RH, Navale L, Amado RG, Schwab G, Figlin RA. PMID: 18223225.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCTClinical Trials
    91. Pathobiology and prognosis of chromophobe renal cell carcinoma. Urol Oncol. 2008 Nov-Dec; 26(6):604-9. Klatte T, Han KR, Said JW, Böhm M, Allhoff EP, Kabbinavar FF, Belldegrun AS, Pantuck AJ. PMID: 18367104.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    92. Proteomic identification of interleukin-2 therapy response in metastatic renal cell cancer. J Urol. 2008 Feb; 179(2):730-6. Jones J, Otu HH, Grall F, Spentzos D, Can H, Aivado M, Belldegrun AS, Pantuck AJ, Libermann TA. PMID: 18082202.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    93. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res. 2007 Dec 15; 13(24):7388-93. Klatte T, Seligson DB, Riggs SB, Leppert JT, Berkman MK, Kleid MD, Yu H, Kabbinavar FF, Pantuck AJ, Belldegrun AS. PMID: 18094421.
      View in: PubMed   Mentions: 68     Fields:    Translation:Humans
    94. Which pathological features of renal cell carcinoma have the greatest prognostic value? Nat Clin Pract Urol. 2008 Feb; 5(2):74-5. La Rochelle J, Belldegrun AS. PMID: 18059390.
      View in: PubMed   Mentions:    Fields:    
    95. Surveillance for renal cell carcinoma: why and how? When and how often? Urol Oncol. 2008 Sep-Oct; 26(5):550-4. Klatte T, Lam JS, Shuch B, Belldegrun AS, Pantuck AJ. PMID: 18774472.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    96. Cytoreductive nephron-sparing surgery does not appear to undermine disease-specific survival in patients with metastatic renal cell carcinoma. Cancer. 2007 Dec 01; 110(11):2428-33. Hutterer GC, Patard JJ, Colombel M, Belldegrun AS, Pfister C, Guille F, Artibani W, Montorsi F, Pantuck AJ, Karakiewicz PI. PMID: 17941033.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    97. In vivo efficacy of laparoscopic assisted percutaneous renal cryotherapy: evidence based guidelines for the practicing urologist. J Urol. 2008 Jan; 179(1):333-7. Breda A, Lam JS, Riggs S, Leppert JT, Gui D, Said JW, Schulam PG, Belldegrun AS. PMID: 18006012.
      View in: PubMed   Mentions: 7     Fields:    Translation:Animals
    98. The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma. J Urol. 2008 Jan; 179(1):61-6. Klatte T, Seligson DB, Leppert JT, Riggs SB, Yu H, Zomorodian N, Kabbinavar FF, Strieter RM, Belldegrun AS, Pantuck AJ. PMID: 17997430.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    99. Update on partial nephrectomy and novel techniques. Urol Oncol. 2007 Nov-Dec; 25(6):520-2. Riggs SB, Klatte T, Belldegrun AS. PMID: 18047964.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    100. A novel resectoscope for transurethral resection of bladder tumors and the prostate. J Urol. 2007 Dec; 178(6):2331-6; discussion 2336. Pantuck AJ, Baniel J, Kirkali Z, Klatte T, Zomorodian N, Yossepowitch O, Belldegrun AS. PMID: 17936809.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    101. Unclassified renal cell carcinoma: an analysis of 85 cases. BJU Int. 2007 Oct; 100(4):802-8. Karakiewicz PI, Hutterer GC, Trinh QD, Pantuck AJ, Klatte T, Lam JS, Guille F, de La Taille A, Novara G, Tostain J, Cindolo L, Ficarra V, Schips L, Zigeuner R, Mulders PF, Chautard D, Lechevallier E, Valeri A, Descotes JL, Lang H, Soulie M, Ferriere JM, Pfister C, Mejean A, Belldegrun AS, Patard JJ. PMID: 17822461.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    102. Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. J Agric Food Chem. 2007 Sep 19; 55(19):7732-7. Seeram NP, Aronson WJ, Zhang Y, Henning SM, Moro A, Lee RP, Sartippour M, Harris DM, Rettig M, Suchard MA, Pantuck AJ, Belldegrun A, Heber D. PMID: 17722872.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansAnimals
    103. Prognostic factors for renal cell carcinoma with tumor thrombus extension. J Urol. 2007 Oct; 178(4 Pt 1):1189-95; discussion 1195. Klatte T, Pantuck AJ, Riggs SB, Kleid MD, Shuch B, Zomorodian N, Kabbinavar FF, Belldegrun AS. PMID: 17698087.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    104. Differential diagnosis of hypercalcemia in renal malignancy. Urology. 2007 Jul; 70(1):179.e7-8. Klatte T, Said JW, Belldegrun AS, Pantuck AJ. PMID: 17656242.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    105. Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance of the primary-free interval. J Urol. 2007 Jun; 177(6):2081-6; discussion 2086-7. Klatte T, Patard JJ, Wunderlich H, Goel RH, Lam JS, Junker K, Schubert J, Böhm M, Allhoff EP, Kabbinavar FF, Crepel M, Cindolo L, De La Taille A, Tostain J, Mejean A, Soulie M, Bellec L, Bernhard JC, Ferriere JM, Pfister C, Albouy B, Colombel M, Zisman A, Belldegrun AS, Pantuck AJ. PMID: 17509291.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    106. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer. 2007 Jun 01; 109(11):2257-67. Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L, O'Toole T, Gibbons J, Belldegrun AS, Figlin RA. PMID: 17440983.
      View in: PubMed   Mentions: 109     Fields:    Translation:HumansCells
    107. Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience. J Urol. 2007 Jul; 178(1):35-40; discussion 40. Klatte T, Patard JJ, Goel RH, Kleid MD, Guille F, Lobel B, Abbou CC, De La Taille A, Tostain J, Cindolo L, Altieri V, Ficarra V, Artibani W, Prayer-Galetti T, Allhoff EP, Schips L, Zigeuner R, Figlin RA, Kabbinavar FF, Pantuck AJ, Belldegrun AS, Lam JS. PMID: 17521678.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    108. The role of molecular markers in the staging of renal cell carcinoma. BJU Int. 2007 May; 99(5 Pt B):1208-11. Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS. PMID: 17441912.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    109. Expression of CXCR3 on mononuclear cells and CXCR3 ligands in patients with metastatic renal cell carcinoma in response to systemic IL-2 therapy. J Immunother. 2007 May-Jun; 30(4):417-24. Reckamp KL, Figlin RA, Moldawer N, Pantuck AJ, Belldegrun AS, Burdick MD, Strieter RM. PMID: 17457216.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    110. Clinicopathological features and prognosis of synchronous bilateral renal cell carcinoma: an international multicentre experience. BJU Int. 2007 Jul; 100(1):21-5. Klatte T, Wunderlich H, Patard JJ, Kleid MD, Lam JS, Junker K, Schubert J, Böhm M, Allhoff EP, Kabbinavar FF, Crepel M, Cindolo L, De La Taille A, Tostain J, Mejean A, Soulie M, Bellec L, Bernhard JC, Ferriere JM, Pfister C, Albouy B, Colombel M, Zisman A, Belldegrun AS, Pantuck AJ. PMID: 17433034.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    111. Platelet count and preoperative haemoglobin do not significantly increase the performance of established predictors of renal cell carcinoma-specific mortality. Eur Urol. 2007 Nov; 52(5):1428-36. Karakiewicz PI, Trinh QD, Lam JS, Tostain J, Pantuck AJ, Belldegrun AS, Patard JJ. PMID: 17420085.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    112. Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience. Eur Urol. 2007 Jul; 52(1):155-62. Lam JS, Klatte T, Patard JJ, Goel RH, Guillè F, Lobel B, Abbou CC, De La Taille A, Tostain J, Cindolo L, Altieri V, Ficarra V, Artibani W, Prayer-Galetti T, Schips L, Zigeuner R, Pantuck AJ, Figlin RA, Belldegrun AS. PMID: 17316970.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    113. Prognostic relevance of capsular involvement and collecting system invasion in stage I and II renal cell carcinoma. BJU Int. 2007 Apr; 99(4):821-4. Klatte T, Chung J, Leppert JT, Lam JS, Pantuck AJ, Figlin RA, Belldegrun AS. PMID: 17244281.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    114. Morbidity and clinical outcome of nephron-sparing surgery in relation to tumour size and indication. Eur Urol. 2007 Jul; 52(1):148-54. Patard JJ, Pantuck AJ, Crepel M, Lam JS, Bellec L, Albouy B, Lopes D, Bernhard JC, Guillé F, Lacroix B, De La Taille A, Salomon L, Pfister C, Soulié M, Tostain J, Ferriere JM, Abbou CC, Colombel M, Belldegrun AS. PMID: 17240036.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    115. Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy? Clin Cancer Res. 2007 Jan 15; 13(2 Pt 2):693s-696s. Pantuck AJ, Belldegrun AS, Figlin RA. PMID: 17255295.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    116. Protein expression profiles in renal cell carcinoma: staging, prognosis, and patient selection for clinical trials. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 2):703s-708s. Lam JS, Pantuck AJ, Belldegrun AS, Figlin RA. PMID: 17255297.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    117. Understanding the natural biology of kidney cancer: implications for targeted cancer therapy. Rev Urol. 2007; 9(2):47-56. Klatte T, Pantuck AJ, Kleid MD, Belldegrun AS. PMID: 17592537.
      View in: PubMed   Mentions:
    118. p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. J Urol. 2007 Jan; 177(1):63-8; discussion 68-9. Weiss RH, Borowsky AD, Seligson D, Lin PY, Dillard-Telm L, Belldegrun AS, Figlin RA, Pantuck AD. PMID: 17162001.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    119. Annexin-I as a potential target for green tea extract induced actin remodeling. Int J Cancer. 2007 Jan 01; 120(1):111-20. Xiao GS, Jin YS, Lu QY, Zhang ZF, Belldegrun A, Figlin R, Pantuck A, Yen Y, Li F, Rao J. PMID: 17019707.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    120. Phase I, open-label, single-center, multiple-dose, dose-escalation clinical study of SUO11248 (sunitinib) in subjects with high-risk prostate cancer who have elected to undergo radical prostatectomy. Curr Urol Rep. 2007 Jan; 8(1):3-4. Pantuck AJ, Zomorodian N, Belldegrun AS. PMID: 17239310.
      View in: PubMed   Mentions: 5     Fields:    
    121. Evolving principles of surgical management and prognostic factors for outcome in renal cell carcinoma. J Clin Oncol. 2006 Dec 10; 24(35):5565-75. Lam JS, Breda A, Belldegrun AS, Figlin RA. PMID: 17158542.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    122. RENCA/carbonic anhydrase-IX: a murine model of a carbonic anhydrase-IX-expressing renal cell carcinoma. Urology. 2006 Nov; 68(5):1132-8. Shvarts O, Janzen N, Lam JS, Leppert JT, Caliliw R, Figlin RA, Belldegrun AS, Zeng G. PMID: 17095063.
      View in: PubMed   Mentions: 4     Fields:    Translation:Animals
    123. Prognostic factors in renal cell carcinoma. Semin Oncol. 2006 Oct; 33(5):563-75. Shuch BM, Lam JS, Belldegrun AS, Figlin RA. PMID: 17045085.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    124. Mammalian target of rapamycin inhibitors in renal cell carcinoma: current status and future applications. Semin Oncol. 2006 Oct; 33(5):607-13. Pantuck AJ, Thomas G, Belldegrun AS, Figlin RA. PMID: 17045090.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    125. Dendritic cell surface calreticulin is a receptor for NY-ESO-1: direct interactions between tumor-associated antigen and the innate immune system. J Immunol. 2006 Sep 15; 177(6):3582-9. Zeng G, Aldridge ME, Tian X, Seiler D, Zhang X, Jin Y, Rao J, Li W, Chen D, Langford MP, Duggan C, Belldegrun AS, Dubinett SM. PMID: 16951317.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    126. Flap endonuclease 1 is overexpressed in prostate cancer and is associated with a high Gleason score. BJU Int. 2006 Aug; 98(2):445-51. Lam JS, Seligson DB, Yu H, Li A, Eeva M, Pantuck AJ, Zeng G, Horvath S, Belldegrun AS. PMID: 16879693.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    127. The sensitivity of testosterone immunoassays and their role in monitoring antiandrogen therapy. Urol Oncol. 2006 Jul-Aug; 24(4):277-8. Leppert JT, Lam JS, Butch AW, Belldegrun AS. PMID: 16818178.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    128. Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis model. . 2006 Jul; 5(7):1754-63. Jin Y, Iwata KK, Belldegrun A, Figlin R, Pantuck A, Zhang ZF, Lieberman R, Rao J. PMID: 16891461.
      View in: PubMed   Mentions:
    129. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res. 2006 Jul 01; 12(13):4018-26. Pantuck AJ, Leppert JT, Zomorodian N, Aronson W, Hong J, Barnard RJ, Seeram N, Liker H, Wang H, Elashoff R, Heber D, Aviram M, Ignarro L, Belldegrun A. PMID: 16818701.
      View in: PubMed   Mentions: 89     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    130. Adjuvant treatment for renal cell carcinoma. Expert Opin Pharmacother. 2006 Apr; 7(6):705-20. Lam JS, Belldegrun AS, Figlin RA. PMID: 16556087.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    131. Long-term outcomes of the surgical management of renal cell carcinoma. World J Urol. 2006 Aug; 24(3):255-66. Lam JS, Belldegrun AS, Pantuck AJ. PMID: 16479388.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    132. Phase-II Study of pomegranate juice for men with prostate cancer and increasing PSA. Curr Urol Rep. 2006 Jan; 7(1):7. Pantuck AJ, Zomorodian N, Belldegrun AS. PMID: 16480662.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    133. Secondary hormonal therapy for advanced prostate cancer. J Urol. 2006 Jan; 175(1):27-34. Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS. PMID: 16406864.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    134. Surveillance strategies for renal cell carcinoma patients following nephrectomy. Rev Urol. 2006; 8(1):1-7. Chin AI, Lam JS, Figlin RA, Belldegrun AS. PMID: 16985554.
      View in: PubMed   Mentions:
    135. Open partial nephrectomy for the treatment of renal cell carcinoma. Curr Urol Rep. 2006 Jan; 7(1):31-8. Shuch B, Lam JS, Belldegrun AS. PMID: 16480666.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    136. Prevention of bladder cancer: a review. Eur Urol. 2006 Feb; 49(2):226-34. Leppert JT, Shvarts O, Kawaoka K, Lieberman R, Belldegrun AS, Pantuck AJ. PMID: 16413099.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimals
    137. Open surgical management of renal cell carcinoma in the era of minimally invasive kidney surgery. BJU Int. 2005 Dec; 96(9):1268-74. Dave DS, Lam JS, Leppert JT, Belldegrun AS. PMID: 16287443.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    138. Tobacco smoking, GSTP1 polymorphism, and bladder carcinoma. Cancer. 2005 Dec 01; 104(11):2400-8. Cao W, Cai L, Rao JY, Pantuck A, Lu ML, Dalbagni G, Reuter V, Scher H, Cordon-Cardo C, Figlin RA, Belldegrun A, Zhang ZF. PMID: 16240451.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    139. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology. 2005 Nov; 66(5 Suppl):1-9. Lam JS, Leppert JT, Figlin RA, Belldegrun AS. PMID: 16194700.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    140. Predicting response to interleukin-2 therapy among patients with renal cell carcinoma. J Immunother. 2005 Sep-Oct; 28(5):427-9. Leppert JT, Lam JS, Belldegrun AS. PMID: 16113598.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    141. Adjuvant therapy of renal cell carcinoma: patient selection and therapeutic options. BJU Int. 2005 Sep; 96(4):483-8. Lam JS, Leppert JT, Belldegrun AS, Figlin RA. PMID: 16104896.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    142. Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma. BJU Int. 2005 Aug; 96(3):281-5. Leppert JT, Lam JS, Pantuck AJ, Figlin RA, Belldegrun AS. PMID: 16042714.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    143. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol. 2005 Aug; 174(2):466-72; discussion 472; quiz 801. Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS. PMID: 16006866.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    144. A molecular classification of papillary renal cell carcinoma. Cancer Res. 2005 Jul 01; 65(13):5628-37. Yang XJ, Tan MH, Kim HL, Ditlev JA, Betten MW, Png CE, Kort EJ, Futami K, Furge KA, Takahashi M, Kanayama HO, Tan PH, Teh BS, Luan C, Wang K, Pins M, Tretiakova M, Anema J, Kahnoski R, Nicol T, Stadler W, Vogelzang NG, Amato R, Seligson D, Figlin R, Belldegrun A, Rogers CG, Teh BT. PMID: 15994935.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    145. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma. Cancer. 2005 Jun 15; 103(12):2517-25. Lam JS, Shvarts O, Said JW, Pantuck AJ, Seligson DB, Aldridge ME, Bui MH, Liu X, Horvath S, Figlin RA, Belldegrun AS. PMID: 15880379.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    146. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol. 2005 Jun; 173(6):1853-62. Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS. PMID: 15879764.
      View in: PubMed   Mentions: 83     Fields:    Translation:Humans
    147. Feasibility of nerve-sparing prostate cryosurgery: applications and limitations in a canine model. J Endourol. 2005 May; 19(4):520-5. Janzen NK, Han KR, Perry KT, Said JW, Schulam PG, Belldegrun AS. PMID: 15910269.
      View in: PubMed   Mentions: 5     Fields:    Translation:Animals
    148. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol. 2005 May; 173(5):1496-501. Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yu H, Shi T, Belldegrun AS, Horvath S, Figlin RA. PMID: 15821467.
      View in: PubMed   Mentions: 56     Fields:    Translation:Humans
    149. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005 Apr 20; 23(12):2763-71. Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Guillé F, Chopin DK, Mulders PF, Wood CG, Swanson DA, Figlin RA, Belldegrun AS, Pantuck AJ. PMID: 15837991.
      View in: PubMed   Mentions: 175     Fields:    Translation:Humans
    150. Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol. 2005 Jul; 23(3):202-12. Lam JS, Leppert JT, Belldegrun AS, Figlin RA. PMID: 15812574.
      View in: PubMed   Mentions: 78     Fields:    Translation:Humans
    151. The effects of intentional cryoablation and radio frequency ablation of renal tissue involving the collecting system in a porcine model. J Urol. 2005 Apr; 173(4):1368-74. Janzen NK, Perry KT, Han KR, Kristo B, Raman S, Said JW, Belldegrun AS, Schulam PG. PMID: 15758807.
      View in: PubMed   Mentions: 23     Fields:    Translation:Animals
    152. Tumor classification by tissue microarray profiling: random forest clustering applied to renal cell carcinoma. Mod Pathol. 2005 Apr; 18(4):547-57. Shi T, Seligson D, Belldegrun AS, Palotie A, Horvath S. PMID: 15529185.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    153. Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: implications as a potential biomarker. Int J Cancer. 2005 Mar 20; 114(2):268-73. Zeng G, Aldridge ME, Wang Y, Pantuck AJ, Wang AY, Liu YX, Han Y, Yuan YH, Robbins PF, Dubinett SM, deKernion JB, Belldegrun AS. PMID: 15540228.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    154. G250: a carbonic anhydrase IX monoclonal antibody. Curr Oncol Rep. 2005 Mar; 7(2):109-15. Lam JS, Pantuck AJ, Belldegrun AS, Figlin RA. PMID: 15717944.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimals
    155. Staging of renal cell carcinoma: current concepts. BJU Int. 2005 Mar; 95 Suppl 2:8-13. Shvarts O, Lam JS, Kim HL, Belldegrun AS. PMID: 15759349.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    156. p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J Urol. 2005 Mar; 173(3):725-8. Shvarts O, Seligson D, Lam J, Shi T, Horvath S, Figlin R, Belldegrun A, Pantuck AJ. PMID: 15711252.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    157. Green tea extract modulates actin remodeling via Rho activity in an in vitro multistep carcinogenic model. Clin Cancer Res. 2005 Feb 15; 11(4):1675-83. Lu QY, Jin YS, Pantuck A, Zhang ZF, Heber D, Belldegrun A, Brooks M, Figlin R, Rao J. PMID: 15746073.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    158. Surveillance following radical or partial nephrectomy for renal cell carcinoma. Curr Urol Rep. 2005 Feb; 6(1):7-18. Lam JS, Leppert JT, Figlin RA, Belldegrun AS. PMID: 15610692.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    159. Advances in immune-based therapies of renal cell carcinoma. Expert Rev Anticancer Ther. 2004 Dec; 4(6):1081-96. Lam JS, Belldegrun AS, Figlin RA. PMID: 15606335.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    160. Symptoms as well as tumor size provide prognostic information on patients with localized renal tumors. J Urol. 2004 Dec; 172(6 Pt 1):2167-71. Patard JJ, Dorey FJ, Cindolo L, Ficarra V, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Chopin DK, Figlin RA, Belldegrun AS, Pantuck AJ. PMID: 15538224.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    161. Tissue array-based predictions of pathobiology, prognosis, and response to treatment for renal cell carcinoma therapy. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 2):6304S-9S. Lam JS, Belldegrun AS, Figlin RA. PMID: 15448022.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    162. Cystic renal cell carcinoma: biology and clinical behavior. Urol Oncol. 2004 Sep-Oct; 22(5):410-4. Han KR, Janzen NK, McWhorter VC, Kim HL, Pantuck AJ, Zisman A, Figlin RA, Dorey FJ, Said JW, Belldegrun AS. PMID: 15464922.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    163. Eastern Cooperative Oncology Group performance status predicts bone metastasis in patients presenting with renal cell carcinoma: implication for preoperative bone scans. J Urol. 2004 Sep; 172(3):867-70. Shvarts O, Lam JS, Kim HL, Han KR, Figlin R, Belldegrun A. PMID: 15310985.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    164. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol. 2004 Aug 15; 22(16):3316-22. Patard JJ, Kim HL, Lam JS, Dorey FJ, Pantuck AJ, Zisman A, Ficarra V, Han KR, Cindolo L, De La Taille A, Tostain J, Artibani W, Dinney CP, Wood CG, Swanson DA, Abbou CC, Lobel B, Mulders PF, Chopin DK, Figlin RA, Belldegrun AS. PMID: 15310775.
      View in: PubMed   Mentions: 63     Fields:    Translation:Humans
    165. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res. 2004 Aug 15; 10(16):5464-71. Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yu H, Shi T, Figlin RA, Horvath S, Belldegrun AS. PMID: 15328185.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    166. Lineage relationship between LNCaP and LNCaP-derived prostate cancer cell lines. Prostate. 2004 Jul 01; 60(2):98-108. Liu AY, Brubaker KD, Goo YA, Quinn JE, Kral S, Sorensen CM, Vessella RL, Belldegrun AS, Hood LE. PMID: 15162376.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    167. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol. 2004 Jun; 171(6 Pt 1):2181-5, quiz 2435. Patard JJ, Shvarts O, Lam JS, Pantuck AJ, Kim HL, Ficarra V, Cindolo L, Han KR, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Chopin DK, Figlin RA, Mulders PF, Belldegrun AS. PMID: 15126781.
      View in: PubMed   Mentions: 116     Fields:    Translation:Humans
    168. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol. 2004 Jun; 171(6 Pt 1):2461-6. Bui MH, Visapaa H, Seligson D, Kim H, Han KR, Huang Y, Horvath S, Stanbridge EJ, Palotie A, Figlin RA, Belldegrun AS. PMID: 15126876.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    169. Cachexia-like symptoms predict a worse prognosis in localized t1 renal cell carcinoma. J Urol. 2004 May; 171(5):1810-3. Kim HL, Han KR, Zisman A, Figlin RA, Belldegrun AS. PMID: 15076282.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    170. Use of American Society of Anesthesiologists physical status classification to assess perioperative risk in patients undergoing radical nephrectomy for renal cell carcinoma. Urology. 2004 May; 63(5):841-6; discussion 846-7. Han KR, Kim HL, Pantuck AJ, Dorey FJ, Figlin RA, Belldegrun AS. PMID: 15134960.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    171. Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer. J Immunother. 2004 May-Jun; 27(3):240-53. Pantuck AJ, van Ophoven A, Gitlitz BJ, Tso CL, Acres B, Squiban P, Ross ME, Belldegrun AS, Figlin RA. PMID: 15076142.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCellsCTClinical Trials
    172. Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clin Cancer Res. 2004 Apr 15; 10(8):2659-69. Seligson DB, Pantuck AJ, Liu X, Huang Y, Horvath S, Bui MH, Han KR, Correa AJ, Eeva M, Tze S, Belldegrun AS, Figlin RA. PMID: 15102668.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    173. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys. 2004 Mar 01; 58(3):984-90. Foon KA, Yang XD, Weiner LM, Belldegrun AS, Figlin RA, Crawford J, Rowinsky EK, Dutcher JP, Vogelzang NJ, Gollub J, Thompson JA, Schwartz G, Bukowski RM, Roskos LK, Schwab GM. PMID: 14967460.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansAnimals
    174. Intraoperative ultrasonography in urologic oncology. Urol Oncol. 2004 Mar-Apr; 22(2):153-5. Belldegrun A, Kim H, Landman J, Wolf JS. PMID: 15082016.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    175. Generation of kidney cancer-specific antitumor immune responses using peripheral blood monocytes transduced with a recombinant adenovirus encoding carbonic anhydrase 9. Clin Cancer Res. 2004 Feb 15; 10(4):1421-9. Mukouyama H, Janzen NK, Hernandez JM, Lam JS, Caliliw R, Wang AY, Figlin RA, Belldegrun AS, Zeng G. PMID: 14977845.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    176. Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different? J Urol. 2004 Feb; 171(2 Pt 1):588-91. Kim HL, Zisman A, Han KR, Figlin RA, Belldegrun AS. PMID: 14713765.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCells
    177. Kidney cancer management in 2004: an update for the practicing general urologist. Curr Urol Rep. 2004 Feb; 5(1):1-3. Lam JS, Shvarts O, Belldegrun AS. PMID: 14733829.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    178. The role of lymphadenectomy in renal cell carcinoma. Curr Urol Rep. 2004 Feb; 5(1):25-9. Kim HL, Lam JS, Belldegrun AS. PMID: 14733833.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    179. Heat shock-peptide complex vaccine as adjuvant therapy for high-risk patients with resected renal cell carcinoma. Curr Urol Rep. 2004 Feb; 5(1):11-2. Shvarts O, Lam J, Figlin R, Belldegrun AS. PMID: 14733830.
      View in: PubMed   Mentions:    Fields:    
    180. Primary leiomyosarcoma of the inferior vena cava presenting as a renal mass. Rev Urol. 2004; 6(1):39-42. Shvarts O, Han KR, Lam JS, Belldegrun AS. PMID: 16985570.
      View in: PubMed   Mentions:
    181. Report from the society of urologic oncology: highlights from the fourth annual meeting of the society of urologic oncology, december 5-6, 2003, bethesda, MD. Rev Urol. 2004; 6(4):193-9. Shvarts O, Lam J, Belldegrun AS. PMID: 16985601.
      View in: PubMed   Mentions:
    182. Salvage cryosurgery of the prostate after radiation failure. Rev Urol. 2004; 6 Suppl 4:S27-36. Lam JS, Belldegrun AS. PMID: 16985867.
      View in: PubMed   Mentions:
    183. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003 Dec 15; 98(12):2566-75. Leibovich BC, Han KR, Bui MH, Pantuck AJ, Dorey FJ, Figlin RA, Belldegrun A. PMID: 14669275.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    184. Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population. J Urol. 2003 Dec; 170(6 Pt 1):2221-4. Han KR, Bleumer I, Pantuck AJ, Kim HL, Dorey FJ, Janzen NK, Zisman A, Dinney CP, Wood CG, Swanson DA, Said JW, Figlin RA, Mulders PF, Belldegrun AS. PMID: 14634383.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    185. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003 Nov; 30(4):843-52. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. PMID: 14680319.
      View in: PubMed   Mentions: 193     Fields:    Translation:Humans
    186. Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J Urol. 2003 Nov; 170(5):1742-6. Kim HL, Belldegrun AS, Freitas DG, Bui MH, Han KR, Dorey FJ, Figlin RA. PMID: 14532767.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    187. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res. 2003 Oct 15; 9(13):4641-52. Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA. PMID: 14581333.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCells
    188. Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. J Urol. 2003 Oct; 170(4 Pt 1):1126-30. Han KR, Cohen JK, Miller RJ, Pantuck AJ, Freitas DG, Cuevas CA, Kim HL, Lugg J, Childs SJ, Shuman B, Jayson MA, Shore ND, Moore Y, Zisman A, Lee JY, Ugarte R, Mynderse LA, Wilson TM, Sweat SD, Zincke H, Belldegrun AS. PMID: 14501706.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    189. Collecting system invasion in renal cell carcinoma: impact on prognosis and future staging strategies. J Urol. 2003 Sep; 170(3):768-72; discussion 772. Palapattu GS, Pantuck AJ, Dorey F, Said JW, Figlin RA, Belldegrun AS. PMID: 12913694.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    190. A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J Immunother. 2003 Sep-Oct; 26(5):412-9. Gitlitz BJ, Belldegrun AS, Zisman A, Chao DH, Pantuck AJ, Hinkel A, Mulders P, Moldawer N, Tso CL, Figlin RA. PMID: 12973030.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    191. Emerging technologies in uroradiologic imaging. Urol Oncol. 2003 Sep-Oct; 21(5):317-26. Janzen NK, Laifer-Narin S, Han KR, Seltzer M, Thomas MA, Pantuck AJ, Belldegrun AS. PMID: 14670537.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    192. LABAZ1: A metastatic tumor model for renal cell carcinoma expressing the carbonic anhydrase type 9 tumor antigen. Cancer Res. 2003 Aug 15; 63(16):4952-9. Zisman A, Pantuck AJ, Bui MH, Said JW, Caliliw RR, Rao N, Shintaku P, Berger F, Gambhir SS, Belldegrun AS. PMID: 12941820.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    193. Current staging of renal cell carcinoma. Urol Clin North Am. 2003 Aug; 30(3):481-97, viii. Leibovich BC, Pantuck AJ, Bui MH, Ryu-Han K, Zisman A, Figlin R, Belldegrun A. PMID: 12953750.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    194. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer. 2003 Jun 15; 97(12):2995-3002. Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, Gitlitz B, Belldegrun AS, Figlin RA. PMID: 12784334.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    195. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol. 2003 Jun; 169(6):2076-83. Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, Gitlitz BJ, Figlin RA, Belldegrun AS. PMID: 12771723.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    196. Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system. Prostate. 2003 Jun 01; 55(4):299-307. Freedland SJ, Pantuck AJ, Paik SH, Zisman A, Graeber TG, Eisenberg D, McBride WH, Nguyen D, Tso CL, Belldegrun AS. PMID: 12712409.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    197. Renal cell carcinoma with tumor thrombus extension into the proximal pulmonary artery. J Urol. 2003 Jun; 169(6):2296-7. Wieder JA, Laks H, Freitas D, Marmureanu A, Belldegrun A. PMID: 12771776.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    198. Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene. Clin Cancer Res. 2003 May; 9(5):1906-16. Hernández JM, Bui MH, Han KR, Mukouyama H, Freitas DG, Nguyen D, Caliliw R, Shintaku PI, Paik SH, Tso CL, Figlin RA, Belldegrun AS. PMID: 12738749.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    199. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. Prostate. 2003 Apr 01; 55(1):71-80. Freedland SJ, Seligson DB, Liu AY, Pantuck AJ, Paik SH, Horvath S, Wieder JA, Zisman A, Nguyen D, Tso CL, Palotie AV, Belldegrun AS. PMID: 12640663.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    200. Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma. Urology. 2003 Apr; 61(4):845-50. Visapää H, Bui M, Huang Y, Seligson D, Tsai H, Pantuck A, Figlin R, Rao JY, Belldegrun A, Horvath S, Palotie A. PMID: 12670587.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    201. 8q24 amplification in transitional cell carcinoma of bladder. Appl Immunohistochem Mol Morphol. 2003 Mar; 11(1):33-6. Visapää H, Seligson D, Eeva M, Gaber F, Rao J, Belldegrun A, Palotie A. PMID: 12610354.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    202. Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. J Urol. 2003 Mar; 169(3):909-16. Zisman A, Wieder JA, Pantuck AJ, Chao DH, Dorey F, Said JW, Gitlitz BJ, deKernion JB, Figlin RA, Belldegrun AS. PMID: 12576811.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    203. Immune gene therapy for kidney cancer: the search for a magic trigger. Mol Ther. 2003 Feb; 7(2):153-4. Kim HL, Belldegrun AS, Figlin RA. PMID: 12597902.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    204. Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes. Int J Oncol. 2003 Feb; 22(2):431-7. Frost P, Caliliw R, Belldegrun A, Bonavida B. PMID: 12527945.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    205. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology. 2003 Feb; 61(2):314-9. Han KR, Pantuck AJ, Bui MH, Shvarts O, Freitas DG, Zisman A, Leibovich BC, Dorey FJ, Gitlitz BJ, Figlin RA, Belldegrun AS. PMID: 12597937.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    206. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003 Feb; 9(2):802-11. Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, Horvath S, Leibovich BC, Chopra S, Liao SY, Stanbridge E, Lerman MI, Palotie A, Figlin RA, Belldegrun AS. PMID: 12576453.
      View in: PubMed   Mentions: 166     Fields:    Translation:Humans
    207. Monoclonal antibody (MAB) in patients with advanced cancer. Curr Urol Rep. 2003 Feb; 4(1):11-2. Kim HL, Pantuck AJ, Zomorodian N, Belldegrun AS. PMID: 12537933.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    208. Basic biology and clinical behavior of renal cell carcinoma. Cancer Treat Res. 2003; 116:69-89. Han KR, Pantuck AJ, Belldegrun AS. PMID: 14650826.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    209. Urologic oncology: extraordinary opportunities for discovery: highlights from the 2nd annual winter meeting of the society of urologic oncology december 1-2, 2001, bethesda, MD. Rev Urol. 2003; 5(1):26-8. Pantuck AJ, Zisman A, Belldegrun AS. PMID: 16985614.
      View in: PubMed   Mentions:
    210. Late relapse of germ-cell tumor. Rev Urol. 2003; 5(3):207-8. Kim HL, Han KR, Belldegrun AS. PMID: 16985645.
      View in: PubMed   Mentions:
    211. Advances in the Treatment of Genitourinary Cancer: Highlights from the 3rd Annual Meeting of the Society of Urologic Oncology, December 13-14, 2002, Washington, DC. Rev Urol. 2003; 5(4):232-4. Palapattu GS, Kim HL, Belldegrun AS. PMID: 16985843.
      View in: PubMed   Mentions:
    212. Lymph node dissection in patients with kidney cancer: when is it indicated? Rev Urol. 2003; 5(3):196-9. Palapattu GS, Kim HL, Belldegrun AS. PMID: 16985641.
      View in: PubMed   Mentions:
    213. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002 Dec 01; 20(23):4559-66. Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, deKernion JB, Figlin RA, Belldegrun AS. PMID: 12454113.
      View in: PubMed   Mentions: 135     Fields:    Translation:Humans
    214. Ki67, gelsolin and PTEN expression in sarcomatoid renal tumors. Urol Res. 2003 Feb; 30(6):387-9. Visapää H, Seligson D, Huang Y, Rao JY, Belldegrun A, Horvath S, Palotie A. PMID: 12599019.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    215. Tissue microarray analysis of cytoskeletal actin-associated biomarkers gelsolin and E-cadherin in urothelial carcinoma. Cancer. 2002 Sep 15; 95(6):1247-57. Rao J, Seligson D, Visapaa H, Horvath S, Eeva M, Michel K, Pantuck A, Belldegrun A, Palotie A. PMID: 12216092.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    216. PC-SPES: herbal formulation for prostate cancer. Urology. 2002 Sep; 60(3):369-75; discussion 376-7. Marks LS, DiPaola RS, Nelson P, Chen S, Heber D, Belldegrun AS, Lowe FC, Fan J, Leaders FE, Pantuck AJ, Tyler VE. PMID: 12350462.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    217. Unclassified renal cell carcinoma: clinical features and prognostic impact of a new histological subtype. J Urol. 2002 Sep; 168(3):950-5. Zisman A, Chao DH, Pantuck AJ, Kim HJ, Wieder JA, Figlin RA, Said JW, Belldegrun AS. PMID: 12187197.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    218. Renal cell carcinoma with tumor thrombus: is cytoreductive nephrectomy for advanced disease associated with an increased complication rate? J Urol. 2002 Sep; 168(3):962-7. Zisman A, Pantuck AJ, Chao DH, Wieder JA, Dorey F, Said JW, Kernion JB, Figlin R, Belldegrun AS. PMID: 12187200.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    219. CL1-SR39: A noninvasive molecular imaging model of prostate cancer suicide gene therapy using positron emission tomography. J Urol. 2002 Sep; 168(3):1193-8. Pantuck AJ, Berger F, Zisman A, Nguyen D, Tso CL, Matherly J, Gambhir SS, Belldegrun AS. PMID: 12187266.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    220. Whole-body skeletal imaging in mice utilizing microPET: optimization of reproducibility and applications in animal models of bone disease. Eur J Nucl Med Mol Imaging. 2002 Sep; 29(9):1225-36. Berger F, Lee YP, Loening AM, Chatziioannou A, Freedland SJ, Leahy R, Lieberman JR, Belldegrun AS, Sawyers CL, Gambhir SS. PMID: 12418463.
      View in: PubMed   Mentions: 22     Fields:    Translation:AnimalsCells
    221. Positron emission tomography in urologic oncology. Cancer Control. 2002 Jul-Aug; 9(4):335-42. Shvarts O, Han KR, Seltzer M, Pantuck AJ, Belldegrun AS. PMID: 12228759.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    222. Optimizing prostate cancer suicide gene therapy using herpes simplex virus thymidine kinase active site variants. Hum Gene Ther. 2002 May 01; 13(7):777-89. Pantuck AJ, Matherly J, Zisman A, Nguyen D, Berger F, Gambhir SS, Black ME, Belldegrun A, Wu L. PMID: 11975845.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    223. Changing concepts in the management of renal oncocytoma. Urology. 2002 May; 59(5):635-42. Chao DH, Zisman A, Pantuck AJ, Freedland SJ, Said JW, Belldegrun AS. PMID: 11992832.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    224. Mathematical model to predict individual survival for patients with renal cell carcinoma. J Clin Oncol. 2002 Mar 01; 20(5):1368-74. Zisman A, Pantuck AJ, Dorey F, Chao DH, Gitlitz BJ, Moldawer N, Lazarovici D, deKernion JB, Figlin RA, Belldegrun AS. PMID: 11870181.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    225. A randomized phase III trial of high dose interleukin-2 versus subcutaneous interleukin-2/interferon. Curr Urol Rep. 2002 Feb; 3(1):11-2. Han KR, Pantuck AJ, Belldegrun AS. PMID: 12084213.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    226. Minimally invasive ablative approaches in the treatment of renal cell carcinoma. Curr Urol Rep. 2002 Feb; 3(1):13-20. Janzen N, Zisman A, Pantuck AJ, Perry K, Schulam P, Belldegrun AS. PMID: 12084214.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    227. Cryosurgical ablation of renal tumors using 1.5-millimeter, ultrathin cryoprobes. Urology. 2002 Jan; 59(1):130-3. Pantuck AJ, Zisman A, Cohen J, Belldegrun A. PMID: 11796298.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    228. Laparoscopic and percutaneous ablative techniques in the treatment of renal cell carcinoma. Rev Urol. 2002; 4(3):103-11. Perry K, Zisman A, Pantuck AJ, Janzen N, Schulam P, Belldegrun AS. PMID: 16985666.
      View in: PubMed   Mentions:
    229. Tumor markers for the early detection of bladder cancer. Front Biosci. 2002 Jan 01; 7:e19-26. Han KR, Pantuck AJ, Belldegrun AS, Rao JY. PMID: 11779696.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    230. Collecting duct renal cell carcinoma: clinical study of a rare tumor. J Urol. 2002 Jan; 167(1):71-4. Chao D, Zisman A, Pantuck AJ, Gitlitz BJ, Freedland SJ, Said JW, Figlin RA, Belldegrun AS. PMID: 11743278.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    231. Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum Gene Ther. 2001 May 20; 12(8):883-92. Belldegrun A, Tso CL, Zisman A, Naitoh J, Said J, Pantuck AJ, Hinkel A, deKernion J, Figlin R. PMID: 11387054.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCellsCTClinical Trials
    232. Efficacy of nephron-sparing surgery for renal cell carcinoma: analysis based on the new 1997 tumor-node-metastasis staging system. J Clin Oncol. 1999 Sep; 17(9):2868-75. Belldegrun A, Tsui KH, deKernion JB, Smith RB. PMID: 10561364.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    Arie's Networks
    Concepts (583)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (33)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _
    ↑